EP4450079A4 - Composition for the treatment of macular degeneration with novel peptide - Google Patents

Composition for the treatment of macular degeneration with novel peptide

Info

Publication number
EP4450079A4
EP4450079A4 EP22907769.8A EP22907769A EP4450079A4 EP 4450079 A4 EP4450079 A4 EP 4450079A4 EP 22907769 A EP22907769 A EP 22907769A EP 4450079 A4 EP4450079 A4 EP 4450079A4
Authority
EP
European Patent Office
Prior art keywords
treatment
composition
macular degeneration
novel peptide
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22907769.8A
Other languages
German (de)
French (fr)
Other versions
EP4450079A1 (en
Inventor
Yunseok Cho
Byul Nim Ahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyebiokorea Inc
Original Assignee
Eyebiokorea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020220119589A external-priority patent/KR102593936B1/en
Application filed by Eyebiokorea Inc filed Critical Eyebiokorea Inc
Publication of EP4450079A1 publication Critical patent/EP4450079A1/en
Publication of EP4450079A4 publication Critical patent/EP4450079A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP22907769.8A 2021-12-13 2022-11-29 Composition for the treatment of macular degeneration with novel peptide Pending EP4450079A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20210178126 2021-12-13
KR1020220119589A KR102593936B1 (en) 2021-12-13 2022-09-21 Composition for treating macular degeneration comprising novel peptides
PCT/KR2022/019093 WO2023113300A1 (en) 2021-12-13 2022-11-29 Composition for treating macular degeneration comprising novel peptide

Publications (2)

Publication Number Publication Date
EP4450079A1 EP4450079A1 (en) 2024-10-23
EP4450079A4 true EP4450079A4 (en) 2025-12-10

Family

ID=86773096

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22907769.8A Pending EP4450079A4 (en) 2021-12-13 2022-11-29 Composition for the treatment of macular degeneration with novel peptide

Country Status (8)

Country Link
EP (1) EP4450079A4 (en)
JP (1) JP2024546906A (en)
CN (1) CN118984715A (en)
AU (1) AU2022412618B2 (en)
CA (1) CA3240607A1 (en)
MX (1) MX2024006997A (en)
WO (1) WO2023113300A1 (en)
ZA (1) ZA202404552B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101794713B1 (en) * 2016-04-08 2017-11-08 주식회사 아이바이오코리아 Pharmaceutical composition for preventing or treating macular degeneration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176202A1 (en) * 2009-05-28 2011-12-29 Glaxo Group Ltd Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye.
KR101721059B1 (en) * 2014-12-26 2017-03-30 주식회사 아이바이오코리아 Pharmaceutical composition for preventing or treating ocular surface disease
EP3539559B1 (en) * 2016-04-08 2020-08-26 Eyebio Korea Collagen type ii alpha-1-based peptide for use in the treatment of macular degeneration
RU2766160C2 (en) * 2017-05-17 2022-02-08 Юю Фарма, Инк. New peptide and pharmaceutical composition for treatment of eye disease, containing peptide as active pharmaceutical ingredient
EP3709658B1 (en) 2018-11-12 2025-03-26 LG Electronics Inc. Method for coding transform coefficient on basis of high frequency zeroing and apparatus therefor
TWI865470B (en) * 2018-11-14 2024-12-11 南韓商柳柳製藥股份有限公司 Peptides and pharmaceutical compositions for treating eye diseases
BR112021023477A2 (en) * 2019-05-21 2022-02-15 Eyebio Korea Novel peptide compound, pharmaceutical composition for preventing or treating inflammation, food composition for preventing or alleviating inflammation and cosmetic composition having an anti-inflammatory effect
CA3170606A1 (en) * 2020-03-05 2021-09-30 Wonsang YU Treatment of inflammatory diseases with peptides and pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101794713B1 (en) * 2016-04-08 2017-11-08 주식회사 아이바이오코리아 Pharmaceutical composition for preventing or treating macular degeneration

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AL-ZAMIL WASEEM ET AL: "Recent developments in age-related macular degeneration: a review", CLINICAL INTERVENTIONS IN AGING, vol. Volume 12, 1 August 2017 (2017-08-01), UK, pages 1313 - 1330, XP093327946, ISSN: 1178-1998, DOI: 10.2147/CIA.S143508 *
See also references of WO2023113300A1 *

Also Published As

Publication number Publication date
CA3240607A1 (en) 2023-06-22
JP2024546906A (en) 2024-12-26
MX2024006997A (en) 2024-06-19
WO2023113300A1 (en) 2023-06-22
AU2022412618A1 (en) 2024-06-27
CN118984715A (en) 2024-11-19
EP4450079A1 (en) 2024-10-23
ZA202404552B (en) 2025-09-25
AU2022412618B2 (en) 2026-02-19

Similar Documents

Publication Publication Date Title
EP3784260A4 (en) COMPOSITION FOR THE TREATMENT OF SKIN CONDITIONS
EP4414374A4 (en) METHOD FOR THE PREPARATION OF N-ALKYLAMINOSIC ACID AND PEPTIDE WITH N-ALKYLAMINOSIC ACID
EP3790563A4 (en) COMPOSITION FOR THE TREATMENT OF SKIN CONDITIONS
EP3990119A4 (en) METHODS AND COMPOSITIONS USING BRD9 ACTIVATION THERAPIES FOR THE TREATMENT OF CANCER AND RELATED DISEASES
EP3643723C0 (en) NEW PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF EYE DISEASES WITH SUCH A NEW PEPTIDE AS ACTIVE INGREDIENT
EP4094754C0 (en) COMPOSITIONS FOR THE TREATMENT AND/OR PREVENTION OF PROTEIN AGENCY DISEASES
EP3625245A4 (en) PEPTIDE COMPOUNDS, CONJUGATE COMPOUNDS AND THEIR USES IN THE TREATMENT OF INFLAMMATORY DISEASES
EP4007633A4 (en) EXON 44-TARGETED NUCLEIC ACIDS AND RECOMBINANT ADENOA-ASSOCIATED VIRUS FOR THE TREATMENT OF DYSTROPHIN-BASED MYOPATHIES
EP3572095A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HTLV-1 ASSOCIATED MYELOPATHIA
EP3579862A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF DISEASES RELATED TO PERMEABILITY OF THE INTESTINAL EPithelium
EP3820468A4 (en) USE OF DELAYED-RELEASE 5-HYDROXYTRYPTOPHAN IN THE TREATMENT OF GASTROINTESTINAL DISEASES
EP3877396C0 (en) POLYPEPTIDES FOR THE TREATMENT OF CANCER
EP4096675C0 (en) Compositions for the treatment of long COVID
EP4058041C0 (en) COMPOSITION FOR THE TREATMENT OF EPITHELIAL LESIONS
EP3561056A4 (en) PEPTIDE FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION
EA202191403A1 (en) COMPOSITION WITH HIGH PROTEIN CONCENTRATION
EP3902976A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF LIME
PL3506923T3 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GROWTH HORMONE DEFICIENCY IN CHILDREN CONTAINING HGH fusion protein
EP3976023C0 (en) COMPOSITIONS CONTAINING CETYLATED FATTY ACIDS FOR USE IN THE TREATMENT OF GASTRIC MUCOUS LINE
EP4440621C0 (en) PEPTIDE DRUG CONJUGATES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP3898645C0 (en) 2-Fluorinated bile acids for the treatment of neurodegenerative diseases
EP4387678A4 (en) Multigene constructs for the treatment of age-related macular degeneration and other complement dysregulation-related diseases
EP3653639A4 (en) POLYPEPTIDE AND COMPOSITION OF IT FOR TREATMENT OF METABOLIC DISEASES
EP4450079A4 (en) Composition for the treatment of macular degeneration with novel peptide
EP4330411A4 (en) Compositions and methods for treating ocular diseases associated with angiogenesis

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240604

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20251110

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/08 20190101AFI20251104BHEP

Ipc: A61P 27/02 20060101ALI20251104BHEP

Ipc: C07K 7/06 20060101ALI20251104BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS